NasdaqGM:TRVIPharmaceuticals
Does JAMA Phase 2b CORAL Data on Nalbuphine ER Reshape The Bull Case For Trevi Therapeutics (TRVI)?
Trevi Therapeutics recently reported that key results from its Phase 2b CORAL trial of oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis have been published in the Journal of the American Medical Association, showing statistically significant reductions in 24-hour cough frequency and a safety profile consistent with prior studies.
Over 60% of treated patients achieving at least a 50% reduction in cough frequency by Week 6 underscores the therapy’s potential to address a...